-grel-/-grel
Antiplatelet drugs, like clopidogrel.
- Drugs ending in -grel-/-grel: 14
- Approved somewhere: 5
- With a US drug page: 4
- Stem
- -grel-/-grel
- Class
- Antiplatelet drugs, like clopidogrel
- Most common targets
- P2RY12 (7), TBXAS1 (2), HTR2A (2), PDE3A, PDE3B (1), TBXA2R (1)
Approved and clinical-stage drugs in ChEMBL whose names ending in -grel-/-grel, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Anagrelide | Approved | PDE3A, PDE3B | Phosphodiesterase 3 inhibitor |
| Cangrelor | Approved | P2RY12 | Purinergic receptor P2Y12 antagonist |
| Prasugrel | Approved | P2RY12 | Purinergic receptor P2Y12 antagonist |
| Ticagrelor | Approved | P2RY12 | Purinergic receptor P2Y12 negative allosteric modulator |
| Clopidogrel | Approved | P2RY12 | Purinergic receptor P2Y12 antagonist |
| Ozagrel | Phase 3 | TBXAS1 | Thromboxane-A synthase inhibitor |
| Sarpogrelate | Phase 3 | HTR2A | Serotonin 2a (5-HT2a) receptor antagonist |
| Selatogrel | Phase 3 | P2RY12 | Purinergic receptor P2Y12 antagonist |
| Elinogrel | Phase 2 | P2RY12 | Purinergic receptor P2Y12 antagonist |
| Igrelimogene litadenorepvec | Phase 2 | — | — |
| Regrelor | Phase 2 | P2RY12 | Purinergic receptor P2Y12 antagonist |
| Sumecigrel | Phase 2 | — | — |
| Terbogrel | Phase 2 | TBXA2R, TBXAS1 | Thromboxane A2 receptor antagonist |
| Temanogrel | Phase 1 | HTR2A | Serotonin 2a (5-HT2a) receptor inverse agonist |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO